Corvus Pharmaceuticals unveils updated data from Phase 1/1b trial
Category: #health  By Saipriya Iyer  Date: 2020-02-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Corvus Pharmaceuticals unveils updated data from Phase 1/1b trial

Corvus Pharmaceuticals, Inc., a clinical-stage science driven biopharmaceutical firm focusing on the commercialization and development of precisely targeted oncology therapies along with biomarker patient enrichment selection, has reportedly announced updated results from its Phase 1/1b clinical-stage trial of CPI-818, the ITK inhibitor of the company, presented in an oral presentation during the 12th edition of Annual T-Cell Lymphoma Forum 2020, held in La Jolla, California.

Chief Medical Officer, Corvus, Mehrdad Mobasher, M.D., stated that the Phase 1/1b clinical-stage trial of CPI-818, company’s covalent ITK inhibitor which is designed to address T-cell lymphomas, has been well enrolled and continues to offer promising clinical data for patients suffering from advanced, obstinate forms of this cancer.

Mobasher further stated that till date, the data shows that the pharmacology and biology of ITK inhibition with CPI-818 has been expected and is proceeding according to the plan. The company is thrilled to provide updated data at the T-cell Lymphoma Forum, a meeting specifically devoted to this difficult to treat cancer family. The company is now ready to proceed the trial to higher doses of drug where the company would evaluate the activity in specific disease groups.

The Phase 1/1b trial of CPI-818 study is presently enrolling patients with various types of progressive, refractory T-cell lymphomas, which includes AITL (angioimmunoblastic T-cell lymphoma), PTCL-NOS (peripheral T-cell lymphoma-not otherwise specified), CTCL (cutaneous T-cell lymphoma), as well as other T-cell lymphomas. The study utilizes an adaptive, extended cohort design to evaluate the safety, select the dose, target occupancy, biomarkers, PK (pharmacokinetics), and effectiveness of CPI-818.

The primary phase of the trial has been evaluating increasing doses in successive groups of patients so as to ascertain the optimum dose. The second phase is likely to evaluate tumor and safety response to this ideal dose of CPI-818 in patients with disease specific cohorts that might be extended based on early signs of potency. The study is also enrolling patients at key medical centers located in Australia, South Korea, and the United States.

Source credit: https://corvuspharma.gcs-web.com/news-releases/news-release-details/corvus-pharmaceuticals-presents-updated-clinical-data-its-phase



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...